|
Canada-0-GrocersRetail Company Direktoryo
|
Company News :
- Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer
Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC) Data on the efficacy and safety of adjuvant
- FDA Approves Alectinib for ALK-Positive Lung Cancer
Alectinib targets cancer cells that have specific changes, called rearrangements, in the ALK gene The drug has been shown to increase how long people with ALK-positive metastatic NSCLC live and has become a mainstay for treatment of people with this form of lung cancer
- FDA approves alectinib as adjuvant treatment for ALK-positive . . .
FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer
- ALK and Lung Cancer - American Lung Association
ALK stands for anaplastic lymphoma kinase It was originally described in lymphoma, but most ALK-positive cancers are in non-small cell lung cancer
- Connecting the Dots: the ALK lung cancer breakthrough
As multiple ALK inhibitors became available, a new question emerged: which drug should be used first, and how should therapy be sequenced after resistance develops? In 2018, Dr Satoshi Yoda at Massachusetts General Hospital received LCRF funding to study how to tailor treatment for ALK-positive lung cancer
- ALK Rearrangements in Lung Cancer – MyPathologyReport
Patients with ALK-rearranged lung cancer have a higher rate of brain metastases than patients with other NSCLC subtypes — both at diagnosis and over the course of treatment
- TRIANA Biomedicines Announces First Patient Dosed in a Phase . . .
ALK+ NSCLC represents an important subset of lung cancer, characterized by a dependence on ALK fusion proteins for its growth and survival
- Genprex Collaborators to Present Positive Preclinical Data on . . .
Research Collaborators Identify Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy REQORSA is a Potential Treatment for ALK-EML4 Positive Translocated Non-Small Cell Lung Cancer REQORSA Boosts Natural Killer (NK) Cell Antitumor Activity AUSTIN, Texas — (March 18, 2026) — Genprex, Inc (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy
- Alectinib in combination with bevacizumab as first-line . . .
Up to 25% of patients with ALK-rearranged non-small cell lung cancer (NSCLC) experience disease progression within the first year of targeted therapy This work reports a phase 2 trial
- A comprehensive evaluation of ALK inhibitors in the first . . .
There are currently six ALK inhibitors available for the first-line treatment of patients diagnosed with ALK-positive advanced non-small cell lung cancer (NSCLC) However, clinicians face challenges in selecting the most appropriate drug for treatment We have collated pertinent evaluative evidence and undertaken a multifaceted assessment of the enrolled medications across five critical
|
|